United States Patent 8,883,196: What the Claims Actually Cover and How the US Landscape Looks
What does US 8,883,196 claim in plain terms?
US 8,883,196 claims methods for female fertility control using a weekly transdermal hormone patch whose adhesive polymer matrix has a specified set of skin permeation enhancers at defined ranges. The claims are written to require both (1) a regimen and (2) a particular adhesive composition.
Claim 1: Weekly regimen plus a defined permeation-enhancer package
Claim 1 requires all of the following elements:
- Dosage form / application
- “A transdermal hormone delivery device” applied to skin
- Includes:
- backing layer
- adhesive polymer matrix affixed to the backing layer
- Adhesive matrix composition
- Contains:
- (a) an adhesive polymer
- (b) a humectant
- (c) a combination of skin permeation enhancing agents consisting essentially of the following components, with ranges given as final percentage by weight of the adhesive polymer matrix after fabrication
- Dimethyl sulfoxide (DMSO): 4% to 12%
- Fatty (C8-C20) alcohol ester of lactic acid: 4.2% to 12.6%
- Lower (C1-C4) alkyl ester of lactic acid: 0.7% to 2.3%
- Capric acid: 3% to 9%
- (d) a progestin
- (e) an estrogen
- Hormone use and regimen
- The method controls fertility when the device is applied in a schedule:
- one device once each week for three consecutive weeks, then
- one week with no device, or a placebo device
Claim 2 and Claim 3: specific hormones
- Claim 2 narrows progestin to levonorgestrel
- Claim 3 narrows estrogen to ethinyl estradiol or 17β-estradiol
Claim 4-7: Fertility control plus menses delay/avoid for a chosen duration
Claim 4 adds an end-use outcome (delay or avoid menses) and changes regimen logic:
- It still requires the same transdermal device structure and the same “consisting essentially of” permeation-enhancer package with the same weight ranges.
- Regimen:
- Apply one device once each week for a selected number of consecutive weeks
- No week in which the device is not applied and no week in which a placebo device is applied
- Outcome:
- Controls fertility while delaying or avoiding menses for a selected time
Claim 5: progestin is levonorgestrel
Claim 6: estrogen is ethinyl estradiol or 17β-estradiol
Claim 7: selected time is between three and six months
How is the claim scope constrained?
1) “Consisting essentially of” locks the permeation package
Claim 1 (and 4) requires the skin permeation enhancer combination to be:
- “consisting essentially of” DMSO + fatty lactic ester + lower lactic ester + capric acid
- With tight “final percentage by weight” ranges
This drafting choice typically narrows freedom to substitute additional permeation enhancers outside the recited list. If an accused product adds a new enhancer beyond what is considered allowable as a minor/insubstantial component, the “consisting essentially of” limitation becomes a central infringement battleground.
2) The regimen is a hard limitation
Two different schedules appear:
- Claim 1: 3 weeks on, 1 week off (or placebo week)
- Claim 4: consecutive weekly applications for a selected number of weeks, with no “off” or placebo week
Regimen design can therefore drive non-infringement even when the adhesive chemistry is similar.
3) Weight-percent boundaries are structural to infringement analysis
The ranges are not open-ended:
- DMSO: 4–12%
- Fatty lactic ester (C8-C20): 4.2–12.6%
- Lower lactic ester (C1-C4): 0.7–2.3%
- Capric acid: 3–9%
Because the claim states the composition is based on “final percentage by weight ... after fabrication,” the relevant composition comparison is not “formulation at receipt,” but post-fabrication matrix content.
4) Hormone species narrowing is only in dependent claims
If progestin and estrogen are not limited to levonorgestrel / ethinyl estradiol / 17β-estradiol, independent Claim 1 can read on other progestins/estrogens. Dependent Claims 2-3 and 5-6 narrow to those specific hormones.
What is the “product concept” at the core of the patent?
US 8,883,196 is not claiming generic “hormone delivery through skin.” It is claiming a weekly transdermal hormone delivery system whose adhesive matrix uses a particular multi-component permeation enhancer system, deployed under specific cycling (Claim 1) or continuous-without-off-week dosing (Claim 4).
In practice, the patent’s value sits at the intersection of:
- patch-like device design (backing + adhesive matrix)
- adhesive chemistry (humectant + a particular permeation enhancer blend with numeric ranges)
- contraceptive regimen mechanics
- menstrual manipulation endpoint for the extended-time claim
Claim-by-claim “scope map” for enforcement and design-arounds
Claim 1 (fertility control): infringement requires matching all required elements
A product or method would need to satisfy:
- Transdermal device with backing + adhesive polymer matrix
- Adhesive polymer matrix includes the specified enhancer blend with the stated ranges
- Progestin and estrogen are present
- Weekly application for 3 weeks, then an off week (or placebo)
Claim 2-3 (fertility control using levonorgestrel and specified estrogens)
Additional narrow elements:
- Progestin = levonorgestrel
- Estrogen = ethinyl estradiol or 17β-estradiol
Claim 4 (fertility control plus menses delay/avoid)
To hit Claim 4, the method must also:
- Use the same device and adhesive enhancer composition
- Apply weekly for a selected consecutive number of weeks
- No off week and no placebo week
- Achieve delaying/avoiding menses “for a selected time”
Claim 7 (time window constraint)
Claim 7 adds:
- selected time between three and six months
This matters because a continuous regimen outside that duration could be structured to avoid the narrower claim, depending on the claim hierarchy and the specific method asserted.
Patent landscape: where US 8,883,196 likely sits relative to adjacent IP
A full US “landscape” requires prosecution history, family members, and citation chains. The only information provided here is the asserted claim text. With that limitation, the landscape can be characterized only at the claim-technology level, not by listing specific competitor patents and their claim charts.
Key landscape axes that determine whether competitors design around
Competitors seeking to avoid US 8,883,196 would likely focus on one or more of these axes:
-
Permeation enhancer composition
- Remove one of the four specified components
- Shift one component outside the claimed weight range
- Replace the enhancer system so it no longer matches the “consisting essentially of” package
-
Adhesive matrix formulation boundary
- Change the “after fabrication” final matrix percentages
- Use an alternate enhancer system with different functional components
-
Dosing schedule
- Use a regimen that does not match:
- 3 weeks on + 1 week off (Claim 1)
- or continuous weekly dosing without off/placebo weeks (Claim 4)
-
Menstrual manipulation duration
- If asserting Claim 7 specifically, avoid the 3 to 6 month selected time window
Likely competitive convergence points
Even without enumerating individual patents, the claims point to predictable convergence areas in the market:
- weekly transdermal contraceptive patches
- adhesive matrices engineered for consistent hormone flux
- permeation enhancer blends that include DMSO and fatty acid derivatives plus lactic esters
That combination suggests the patent is positioned to capture not just regimen logic but the adhesive formulation strategy used to make weekly dosing feasible.
Key claim construction levers (what will matter in disputes)
-
Scope of “skin permeation enhancing agents consisting essentially of”
- Will additional permeation enhancers be treated as allowable minor components or as excluded material?
-
Meaning of “final percentage by weight ... after fabrication”
- How is “after fabrication” determined in accused devices?
- Whether manufacturing loss or absorption changes percentages post-processing will be a factual issue.
-
Regimen implementation
- Whether “one week in which the device is not applied, or a placebo device is applied” is strictly followed, including labeling instructions and actual administration.
-
“Selected number of consecutive weeks”
- How selection is practiced and documented for the delaying/avoiding menses use.
Key Takeaways
- US 8,883,196 is a transdermal contraceptive method patent that requires both (i) a weekly application regimen and (ii) a specific adhesive matrix permeation enhancer package with numeric weight ranges and “consisting essentially of” language.
- The patent’s strongest constraints are:
- permeation enhancer identity and weight ranges (DMSO, fatty lactic ester C8-C20, lower lactic ester C1-C4, capric acid)
- application schedule (3 weeks on + 1 week off/placebo for Claim 1; continuous weekly without off/placebo week for Claim 4)
- menses timing window (Claim 7: 3 to 6 months)
- Design-around opportunities concentrate on changing the enhancer blend, the matrix percentages, and the dosing schedule.
FAQs
1) What is the central limitation that most likely distinguishes infringement from generic transdermal hormone patches?
The requirement that the adhesive polymer matrix includes a “consisting essentially of” blend of DMSO, fatty (C8-C20) lactic acid ester, lower (C1-C4) lactic acid ester, and capric acid at the specified final weight percentages after fabrication.
2) Does the patent cover weekly use only?
The claims shown require one device once each week. Claim 1 uses a 3-weeks-on/1-week-off (or placebo) pattern; Claim 4 uses continuous consecutive weekly applications with no off/placebo week.
3) Are levonorgestrel and specific estrogens required for all claims?
No. Levonorgestrel and the specific estrogens (ethinyl estradiol or 17β-estradiol) appear in dependent claims (Claims 2, 3, 5, 6). Independent Claims 1 and 4 recite progestin and estrogen more broadly.
4) What changes between Claim 1 and Claim 4?
Claim 4 adds a menses delay/avoid endpoint and changes the regimen to selected consecutive weeks with no off/placebo week, while keeping the same adhesive permeation enhancer package.
5) How does Claim 7 narrow the commercial use case?
Claim 7 specifies the selected time is between three and six months, which can narrow asserted scope if a competitor targets shorter or longer menstrual suppression windows.
References
No external sources were cited because the input provided includes only the claim text and does not include the patent document metadata needed for reliable bibliographic citation.
